WO2002039995A3 - Combination therapy for estrogen-dependent disorders - Google Patents

Combination therapy for estrogen-dependent disorders Download PDF

Info

Publication number
WO2002039995A3
WO2002039995A3 PCT/US2001/043847 US0143847W WO0239995A3 WO 2002039995 A3 WO2002039995 A3 WO 2002039995A3 US 0143847 W US0143847 W US 0143847W WO 0239995 A3 WO0239995 A3 WO 0239995A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination therapy
estrogen
dependent disorders
ovaries
testis
Prior art date
Application number
PCT/US2001/043847
Other languages
French (fr)
Other versions
WO2002039995A2 (en
WO2002039995A9 (en
Inventor
Dinesh Purandare
Original Assignee
Upjohn Co
Dinesh Purandare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200300572A priority Critical patent/EA200300572A1/en
Priority to US10/416,844 priority patent/US20040043938A1/en
Priority to MXPA03004195A priority patent/MXPA03004195A/en
Priority to IL15581701A priority patent/IL155817A0/en
Application filed by Upjohn Co, Dinesh Purandare filed Critical Upjohn Co
Priority to NZ525720A priority patent/NZ525720A/en
Priority to AU2002230464A priority patent/AU2002230464A1/en
Priority to CA002428249A priority patent/CA2428249A1/en
Priority to JP2002542370A priority patent/JP2004536022A/en
Priority to EP01990699A priority patent/EP1341549A2/en
Priority to BR0115423-0A priority patent/BR0115423A/en
Priority to KR10-2003-7006608A priority patent/KR20030051828A/en
Publication of WO2002039995A2 publication Critical patent/WO2002039995A2/en
Publication of WO2002039995A9 publication Critical patent/WO2002039995A9/en
Publication of WO2002039995A3 publication Critical patent/WO2002039995A3/en
Priority to NO20032206A priority patent/NO20032206L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a combination therapy for treating estrogen dependent cancers in susceptible mammals, including humans, comprising the steps of inhibiting hormone output of their testis or ovaries, respectively, and administering to said mammal at least one aromatase inhibitor.
PCT/US2001/043847 2000-11-16 2001-11-06 Combination therapy for estrogen-dependent disorders WO2002039995A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AU2002230464A AU2002230464A1 (en) 2000-11-16 2001-11-06 Combination therapy for estrogen-dependent disorders
MXPA03004195A MXPA03004195A (en) 2000-11-16 2001-11-06 Combination therapy for estrogen-dependent disorders.
IL15581701A IL155817A0 (en) 2000-11-16 2001-11-06 Combination therapy for estrogen-dependent disorders
JP2002542370A JP2004536022A (en) 2000-11-16 2001-11-06 Combination therapy for estrogen-dependent diseases
NZ525720A NZ525720A (en) 2000-11-16 2001-11-06 The use of triptorelin and exemestane in the manner of a medicament for treating a sex steroid dependent cancer
US10/416,844 US20040043938A1 (en) 2001-11-06 2001-11-06 Combination therapy for estrogen-dependent disorders
CA002428249A CA2428249A1 (en) 2000-11-16 2001-11-06 Combination therapy for estrogen-dependent disorders
EA200300572A EA200300572A1 (en) 2000-11-16 2001-11-06 COMBINED THERAPY OF ESTROGEN-DEPENDENT DISEASES
EP01990699A EP1341549A2 (en) 2000-11-16 2001-11-06 Combination therapy for estrogen-dependent disorders
BR0115423-0A BR0115423A (en) 2000-11-16 2001-11-06 Use of an aromatase inhibitor, use of exemestane and triptorelin or a pharmaceutically acceptable salt thereof, and, product
KR10-2003-7006608A KR20030051828A (en) 2000-11-16 2001-11-06 Combination therapy for estrogen-dependent disorders
NO20032206A NO20032206L (en) 2000-11-16 2003-05-15 Combination therapy for estrogen-dependent disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71460500A 2000-11-16 2000-11-16
US09/714,605 2000-11-16

Publications (3)

Publication Number Publication Date
WO2002039995A2 WO2002039995A2 (en) 2002-05-23
WO2002039995A9 WO2002039995A9 (en) 2003-02-06
WO2002039995A3 true WO2002039995A3 (en) 2003-05-01

Family

ID=24870727

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/043847 WO2002039995A2 (en) 2000-11-16 2001-11-06 Combination therapy for estrogen-dependent disorders

Country Status (16)

Country Link
EP (1) EP1341549A2 (en)
JP (1) JP2004536022A (en)
KR (1) KR20030051828A (en)
CN (1) CN1498112A (en)
AU (1) AU2002230464A1 (en)
BR (1) BR0115423A (en)
CA (1) CA2428249A1 (en)
CZ (1) CZ20031349A3 (en)
EA (1) EA200300572A1 (en)
IL (1) IL155817A0 (en)
MX (1) MXPA03004195A (en)
NO (1) NO20032206L (en)
NZ (1) NZ525720A (en)
PL (1) PL365904A1 (en)
WO (1) WO2002039995A2 (en)
ZA (1) ZA200303669B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
GB0506759D0 (en) * 2005-04-02 2005-05-11 Medical Res Council Combination treatment methods
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US20080261933A1 (en) * 2007-04-23 2008-10-23 Jens Hoffmann Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases
CN101775054B (en) * 2010-02-05 2012-12-26 常州佳尔科药业集团有限公司 Synthesis method of 4-hydroxyl-4-alkene-3-ketone steroide compound

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069467A1 (en) * 1999-05-18 2000-11-23 Pharmacia & Upjohn S.P.A. Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
WO2001049294A1 (en) * 1999-12-30 2001-07-12 Pharmacia Italia S.P.A. Product for treating gynecomastia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069467A1 (en) * 1999-05-18 2000-11-23 Pharmacia & Upjohn S.P.A. Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
WO2001049294A1 (en) * 1999-12-30 2001-07-12 Pharmacia Italia S.P.A. Product for treating gynecomastia

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
BAJETTA E ET AL: "The Minimal Effective Exemestane Dose for Endocrine Activity in Advanced Breast Cancer", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 33, no. 4, April 1997 (1997-04-01), pages 587 - 591, XP004282560, ISSN: 0959-8049 *
BENALI NAOUAL ET AL: "Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 16, 1 August 2000 (2000-08-01), pages 9180 - 9185, XP002165128, ISSN: 0027-8424 *
BRODIE A M H ET AL: "Aromatase inhibitors and their application in breast cancer treatment*", STEROIDS, BUTTERWORTH-HEINEMANN, STONEHAM, MA, US, vol. 65, no. 4, April 2000 (2000-04-01), pages 171 - 179, XP004202992, ISSN: 0039-128X *
BRODIE A M H ET AL: "AROMATASE INHIBITORS IN ADVANCED BREAST CANCER: MECHANISM OF ACTIONAND CLINICAL IMPLICATIONS", JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, ELSEVIER SCIENCE LTD., OXFORD, GB, vol. 66, no. 1/2, July 1998 (1998-07-01), pages 1 - 10, XP000986681, ISSN: 0960-0760 *
CELIO LUIGI ET AL: "Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study.", ANTICANCER RESEARCH, vol. 19, no. 3B, May 1999 (1999-05-01), pages 2261 - 2268, XP000986987, ISSN: 0250-7005 *
DATABASE CANCERLIT AN= 91676029 [online] COMARU-SCHALLY A M ET AL: "LHRH AGONISTS AS ADJUNCTS TO SOMATOSTATIN ANALOGS IN THE TREATMENT OF PANCREATIC CANCER.", XP002213988, retrieved from STN Database accession no. 91676029 *
DOEHN C ET AL: "Technology evaluation: Abarelix, Praecis pharmaceuticals.", CURRENT OPINION IN MOLECULAR THERAPEUTICS. ENGLAND OCT 2000, vol. 2, no. 5, October 2000 (2000-10-01), pages 579 - 585, XP001105426, ISSN: 1464-8431 *
DOWSETT MITCHELL ET AL: "Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer.", BREAST CANCER RESEARCH AND TREATMENT, vol. 56, no. 1, July 1999 (1999-07-01), pages 25 - 34, XP001069646, ISSN: 0167-6806 *
EXEMESTANE STUDY GROUP THURLIMANN B ET AL: "Third-Line Hormonal Treatment with Exemestane in Postmenopausal Patients with Advanced Breast Cancer Progressing on Aminoglutethimide: a Phase II Multicentre Multinational Study", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 33, no. 11, October 1997 (1997-10-01), pages 1767 - 1773, XP004284524, ISSN: 0959-8049 *
GNRH ANALOGUES CANCER HUMAN REPRODUCTION, (1990) 3 203-10., Veterans Administration Medical Center, 1601 Perdido St., New Orleans, LA 70146. *
KARP J E ET AL: "Prostate cancer prevention: investigational approaches and opportunities.", CANCER RESEARCH. UNITED STATES 15 DEC 1996, vol. 56, no. 24, 15 December 1996 (1996-12-15), pages 5547 - 5556, XP002113055, ISSN: 0008-5472 *
KELLOFF G J ET AL: "Aromatase inhibitors as potential cancer chemopreventives.", CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION: A PUBLICATION OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, COSPONSORED BY THE AMERICAN SOCIETY OF PREVENTIVE ONCOLOGY. UNITED STATES JAN 1998, vol. 7, no. 1, January 1998 (1998-01-01), pages 65 - 78, XP001105199, ISSN: 1055-9965 *
LONNING P E ET AL: "ACTIVITY OF EXEMESTANE IN METASTATIC BREAST CANCER AFTER FAILURE OF NONSTEROIDAL AROMATASE INHIBITORS: A PHASE II TRIAL", JOURNAL OF CLINICAL ONCOLOGY, PHILADELPHIA, PA, US, vol. 18, no. 11, June 2000 (2000-06-01), pages 2234 - 2244, XP001034132 *
LONNING PER E: "Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.", BREAST CANCER RESEARCH AND TREATMENT, vol. 49, no. SUPPL. 1, 1998, pages S45 - S52, XP001105373, ISSN: 0167-6806 *
MANETTA A ET AL: "INHIBITION OF GROWTH OF HUMAN OVARIAN CANCER IN NUDE MICE BY LUTEINIZING HORMONE-RELEASING HORMONE ANTAGONIST CETRORELIX (SB-75)", FERTILITY AND STERILITY, ELSEVIER SCIENCE INC, NEW YORK, NY, US, vol. 63, no. 2, 1 February 1995 (1995-02-01), pages 282 - 287, XP002088625, ISSN: 0015-0282 *
MILLAR J L: "Triptorelin approved for prostate cancer treatment.", AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY: AJHP: OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS. UNITED STATES 1 AUG 2000, vol. 57, no. 15, 1 August 2000 (2000-08-01), pages 1386, XP001105066, ISSN: 1079-2082 *
MONTAGNANI M M ET AL: "EFFECTS OF LHRH AGONISTS ON THE GROWTH OF HUMAN PROSTATIC TUMOR CELLS: IN VITRO AND IN VIVO STUDIES", ARCHIVIO ITALIANO DI UROLOGIA, LICINIO COPPELLI, BOLOGNA, IT, vol. 69, no. 4, September 1997 (1997-09-01), pages 257 - 263, XP002927944, ISSN: 0365-351X *
NORMAN P: "CETRORELIX ASTA MEDICA AG", CURRENT OPINION IN ONCOLOGIC, ENDOCRINE AND METABOLIC INVESTIGATIONAL DRUGS, CURRENT DRUGS, LONDON,, GB, vol. 2, no. 2, 2000, pages 227 - 248, XP000982761, ISSN: 1464-8466 *
REISSMANN T ET AL: "The LHRH antagonist cetrorelix: a review.", HUMAN REPRODUCTION UPDATE. ENGLAND 2000 JUL-AUG, vol. 6, no. 4, July 2000 (2000-07-01), pages 322 - 331, XP001097713, ISSN: 1355-4786 *
SCOTT LESLEY J ET AL: "Exemestane.", DRUGS, vol. 58, no. 4, October 1999 (1999-10-01), pages 675 - 680, XP001104951, ISSN: 0012-6667 *
STEIN R C ET AL: "THE CLINICAL AND ENDOCRINE EFFECTS OF 4 HYDROXYANDROSTENEDIONE ALONE AND IN COMBINATION WITH GOSERELIN IN PREMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER", BRITISH JOURNAL OF CANCER, vol. 62, no. 4, 1990, pages 679 - 683, XP001069642, ISSN: 0007-0920 *
TSUCHIYA NAOKO ET AL: "Effects of fadrozole and leuprorelin acetate on aromatase activity and cell proliferation in a human breast cancer cell line (SK-BR-3).", INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol. 5, no. 3, June 2000 (2000-06-01), pages 183 - 187, XP001069659, ISSN: 1341-9625 *
WISEMAN L R ET AL: "Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.", DRUGS. NEW ZEALAND JAN 1993, vol. 45, no. 1, January 1993 (1993-01-01), pages 66 - 84, XP001105072, ISSN: 0012-6667 *

Also Published As

Publication number Publication date
CN1498112A (en) 2004-05-19
JP2004536022A (en) 2004-12-02
NO20032206D0 (en) 2003-05-15
AU2002230464A1 (en) 2002-05-27
EA200300572A1 (en) 2004-06-24
NO20032206L (en) 2003-07-15
WO2002039995A2 (en) 2002-05-23
MXPA03004195A (en) 2003-09-22
ZA200303669B (en) 2004-05-13
IL155817A0 (en) 2003-12-23
CZ20031349A3 (en) 2004-05-12
KR20030051828A (en) 2003-06-25
PL365904A1 (en) 2005-01-10
EP1341549A2 (en) 2003-09-10
CA2428249A1 (en) 2002-05-23
BR0115423A (en) 2005-12-13
NZ525720A (en) 2006-12-22
WO2002039995A9 (en) 2003-02-06

Similar Documents

Publication Publication Date Title
WO2002005791A3 (en) Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor
WO2001051043A3 (en) Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
WO2000038730A3 (en) Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
WO2002072031A3 (en) Substituted tetracycline compounds as synergistic antifungal agents
AU4421599A (en) Methods and compositions for controlling iron stores to treat and cure disease states and reduce aging
GB0001449D0 (en) Compositions
MY137766A (en) Exemestane as chemopreventing agent
NO20030955L (en) Procedures for the treatment of erectile dysfunction and increase in libido in humans
WO2002072022A3 (en) Substituted tetracycline compounds as antifungal agents
IL139907A0 (en) Topical transdermal treatments
PL377855A1 (en) Formulations and methods for treating rhinosinusitis
HK1038184A1 (en) Topical hormonal composition with systemic effect.
ZA981132B (en) Methods, compositions and articles for reducing or preventing the effects of inflammation.
PL319295A1 (en) Combination of prostacycline with estrogen or progestin for preventing and treating atherosclerotic diseases, including preeclampsia and hypertension as well as for hormone substitution therapy
LV12342A (en) Progesterone for treating or relieving ischemia
WO2002058706A3 (en) Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
AU2001245977A1 (en) Method and composition for preventing or reducing the symptoms of menopause
IL157436A0 (en) Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
WO2002039995A3 (en) Combination therapy for estrogen-dependent disorders
WO2002009683A3 (en) Aldosterone blocker therapy to prevent or treat inflammation-related disorders
WO2003013554A3 (en) Aromatase inhibitors from broussonetia papyrifera
AU7360000A (en) Methods and compositions for preventing and treating prostate disorders
WO2000072835A3 (en) Topical application of muscarinic and opioid agents for treatment of tinnitus
MXPA04005417A (en) Use of an h1.
MY122838A (en) Treating allergic and inflammatory conditions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1-8, DESCRIPTION, REPLACED BY NEW PAGES 1-8; PAGES 9-12, CLAIMS, REPLACED BY NEW PAGES 9-12; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 2002230464

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2428249

Country of ref document: CA

Ref document number: 525720

Country of ref document: NZ

Ref document number: 2002542370

Country of ref document: JP

Ref document number: 587/KOLNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 155817

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003/03669

Country of ref document: ZA

Ref document number: PA/a/2003/004195

Country of ref document: MX

Ref document number: 200303669

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020037006608

Country of ref document: KR

Ref document number: 018189385

Country of ref document: CN

Ref document number: PV2003-1349

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1-2003-500378

Country of ref document: PH

Ref document number: 03041069

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2001990699

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200300572

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020037006608

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001990699

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10416844

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-1349

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: PI0115423

Country of ref document: BR